Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity

• Published in: Clinical obesity Vol. 8; no. 1; pp. 1 - 10
• Main Authors: Kolotkin, R. L., Gabriel Smolarz, B., Meincke, H. H., Fujioka, K.
• Format: Journal Article
• Language: English
• Published: Chichester, UK Blackwell Publishing Ltd 01-02-2018
• Subjects: Adolescent; Adult; Aged; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Cost of Illness; Double-Blind Method; Female; Health Status; Humans; Incretins - administration & dosage; Incretins - adverse effects; IWQOL‐Lite; Liraglutide - administration & dosage; Liraglutide - adverse effects; liraglutide 3.0 mg; Male; Mental Health; Middle Aged; Obesity - diagnosis; Obesity - drug therapy; Obesity - physiopathology; Obesity - psychology; Original; Quality of Life; SF‐36 v2; Surveys and Questionnaires; Time Factors; Treatment Outcome; weight loss; Weight Loss - drug effects; Young Adult; SF-36 v2; weight loss; IWQOL-Lite; liraglutide 3.0 mg
• ISSN: 1758-8103; 1758-8111
• DOI: 10.1111/cob.12226

Summary
Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health‐related quality of life (HRQoL) than those receiving placebo. The current study extends these findings by examining 3‐year changes in HRQoL. HRQoL was assessed using the obesity‐specific Impact of Weight on Quality of Life‐Lite (IWQOL‐Lite) questionnaire, as well as the Short‐Form 36 v2 (SF‐36) health survey. At 3 years, mean change (±standard deviation) in IWQOL‐Lite total score from baseline for liraglutide (n = 1472) was 11.0 ± 14.2, vs. 8.1 ± 14.7 for placebo (n = 738) (estimated treatment difference [ETD] 3.4 [95% confidence interval (CI): 2.0, 4.7], P < 0.0001). Mean change in SF‐36 physical component summary (PCS) score from baseline for liraglutide was 3.1 ± 7.3, vs. 2.6 ± 7.6 for placebo (ETD 0.87 [95% CI: 0.17, 1.6], P = 0.0156). Mean change in SF‐36 mental component summary score did not significantly differ between groups. Both IWQOL‐Lite total score and PCS score demonstrated an association between greater HRQoL improvement with higher weight loss. Liraglutide 3.0 mg was also associated with improved health utility (Short‐Form‐6D and EuroQol‐5D, mapped from IWQOL‐Lite and/or SF‐36) vs. placebo. Liraglutide 3.0 mg, plus diet and exercise, is associated with long‐term improvements in HRQoL with obesity or overweight with comorbidity vs. placebo.